XUP.F Genfit SA

Healthcare Biotechnology Frankfurt Exchange
10.72 EUR
Close of Nov 13, 2026
3.66 14.86
Market cap
EUR 537M
P/E
-
P/B
3.31x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is XUP.F undervalued?

Graham number

The Graham number of Genfit SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genfit SA fundamental analysis

No fundamental analysis for Genfit SA yet.

Genfit SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genfit SA

Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, w…

Full company profile